anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to the development of monoclonal antibodies that specifically inhibit DNA gyrase from  M. tuberculosis. M. smegmaris  and possibly from other related bacterial species. More particularly, it has been shown that the inhibition of the enzyme is by a hitherto unknown and novel mechanism. The present invention also relates to a DNA sequence of single chain antibody consisting of complementarity determining regions of mAb. The monoclonal antibody, single chain antibody and peptides derived thereof could be useful for developing lead molecules for tuberculosis therapy. The antibodies and derived materials could be useful for a variety of purposes, including diagnosis of mycobacterial infections. The present invention also relates to the modification of antibodies and derived materials for use against diverse microbial infections and other potential applications derived thereof.
[Problem] To provide a report output program which, when a change occurs in a subject, is capable of outputting a report visualizing trends in a sleeping state of the subject before and after the change. [Solution] This report output program causes a computer to output a report relating to a subject, and is a report output program for causing the computer to execute a process including procedures (a) to (d). Procedure (a) acquires information relating to a change in a subject from stored information relating to the subject. Procedure (b) acquires information relating to a sleeping state of the subject, accumulated during a predetermined period including the day on which the change occurred, on the basis of the information relating to the change, acquired in procedure (a). Procedure (c) creates a report including a result in which the sleeping state trend has been visualized, on the basis of the information relating to the sleeping state, acquired in procedure (b). Procedure (d) outputs the report created in procedure (c).
A method for accurately administering a substance to a subject in motion is provided including obtaining one or more scans of the subject. The subject has at least one defined target region thereon for delivery of the substance. A three dimensional position of the subject in motion is calculated based on the obtained one or more scans of the subject. The three dimensional position includes X, Y, and Z coordinates defining the three dimensional position. A timing adjustment is calculated based on the calculated three dimensional position of the subject in motion. A timing of the delivery of the substance to the at least one defined target region is adjusted based on the subject using the calculated timing adjustment. The obtaining, calculating the three dimensional position, calculating the timing adjustment and the adjusting are performed by at least one processor.
Intellectual disability is a heterogeneous disorder, diagnosed using intelligence quotient (IQ) score criteria. Currently, no specific clinical test is available to diagnose the disease and its subgroups due to inadequate understanding of the pathophysiology. Therefore, current study was designed to explore the molecular mechanisms involved in disease perturbation, and to identify potential biomarkers for disease diagnosis and prognosis. A total of 250 participants were enrolled in this study, including 200 intellectually disabled (ID) subjects from the subgroups (mild, moderate, and severe) with age and gender matched healthy controls (n = 50). Initially, IQ testing score and biochemical profile of each subject was generated, followed by label-free quantitative proteomics of subgroups of IQ and healthy control group through nano-LC/MS- mass spectrometry. A total of 310 proteins were identified, among them198 proteins were common among all groups. Statistical analysis (ANOVA) of the subgroups of ID showed 142 differentially expressed proteins, in comparison to healthy control group. From these, 120 proteins were found to be common among all subgroups. The remaining 22 proteins were categorized as exclusive proteins found only in disease subgroups. Furthermore, the hierarchical cluster analysis (HCL) of common significant proteins was also performed, followed by PANTHER protein classification and GO functional enrichment analysis. Results provides that the datasets of differentially expressed proteins, belong to the categories of immune / defense proteins, transfer carrier proteins, apolipoproteins, complement proteins, protease inhibitors, hemoglobin proteins etc., they are known to involvein immune system, and complement and coagulation pathway cascade and cholesterol metabolism pathway. Exclusively expressed 22 proteins were found to be disease stage specific and strong PPI network specifically those that have significant role in platelets activation and degranulation, such as Filamin A (FLNA). Furthermore, to validate the mass spectrometric findings, four highly significant proteins (APOA4, SAP, FLNA, and SERPING) were quantified by ELISA in all the study subjects. AUROC analysis showed a significant association of APOA4 (0.830), FLNA (0.958), SAP (0.754) and SERPING (0.600) with the disease. Apolipoprotein A4 (APOA4) has a significant role in cholesterol transport, and in modulation of glucose and lipid metabolism in the CNS. Similarly, FLNA has a crucial role in the nervous system, especially in the functioning of synaptic network. Therefore, both APOA4, and FLNA proteins represent good potential for candidate biomarkers for the diagnosis and prognosis of the intellectual disability. Overall, serum proteome of ID patients provides valuable information of proteins/pathways that are altered during ID progression.
BACKGROUND: Soft tissue sarcomas (STSs) are a heterogeneous group of tumors. Wide surgical resection is standard, often combined with neoadjuvant chemotherapy, radiotherapy, or both. Studies have shown the predictive value of tumor necrosis in bone sarcoma (BS); however, the role of necrosis in STS after neoadjuvant therapies is still unclear. This study aimed to investigate the role of chemo- and radiotherapy in the formation of tumor necrosis and to evaluate the influence of tumor necrosis on overall survival and local recurrence-free survival. Data from BS patients and patients who did not receive neoadjuvant therapy were compared.
METHODS: A total of 779 patients with STS or BS were treated surgically. In all patients, tumor-specific factors such as type, size, or grading and the type of adjuvant therapy were documented. Local recurrence (LR), the diagnosis of metastatic disease, and survival during follow-up were evaluated.
RESULTS: A total of 565 patients with STS and 214 with BS were investigated. In STS, 24.1% G1 lesions, 34.1% G2 lesions, and 41.8% G3 lesions were observed. Two hundred twenty-four of the patients with STS and neoadjuvant therapy had either radiotherapy (RTx) (n = 80), chemotherapy (CTx) (n = 93), or both (n = 51). Three hundred forty-one had no neoadjuvant therapy at all. In STS, tumor necrosis after neoadjuvant treatment was significantly higher (53.5%) than in patients without neoadjuvant therapy (15.7%) (p < 0.001). Patients with combined neoadjuvant chemo-/radiotherapy had substantially higher tumor necrosis than those with radiotherapy alone (p = 0.032). There was no difference in tumor necrosis in patients with combined chemo-/radiotherapy and chemotherapy alone (p = 0.4). The mean overall survival for patients with STS was 34.7 months. Tumor necrosis did not influence survival in a subgroup of G2/3 patients. In STS with no neoadjuvant therapy and grading of G2/3, the correlation between necrosis and overall survival was significant (p = 0.0248). There was no significant correlation between local recurrence (LR) and necrosis.
CONCLUSION: STS shows a broad spectrum of necrosis even without neoadjuvant chemo- or radiotherapy. After CTx or/and RTx necrosis is enhanced and is significantly pronounced with a combination of both. There is a trend toward higher necrosis with CTx than with RTx. Grading substantially influences the necrosis rate, but necrosis in soft-tissue sarcoma following neoadjuvant therapy does not correlate with better survival or a lower local recurrence rate, as in bone sarcomas.
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having strong α-glucosidase inhibitory activity, being readily taken by making the inhibitor include a Chinese herb as an active ingredient. SOLUTION: This inhibitor contains a Chinese herb as an active ingredient. For example, Magnolia bark, Artemisiae capillaris flos, Citrus Unshiu Peel, Evodia rutaecarpa, peppermint, Platycodon grandiflorum, Lycium chinense, Schizandra chinensis, etc., may be cited as the Chinese herb. Though the Chinese herb is used in an ordinary state, further dried and powdered or ground in water into a slurried state and the slurried Chinese herb may show glucosidase inhibitory activity, an extract obtained by using water and/or an alcohol preferably provides stronger α-glucosidase inhibitory activity. An extract obtained by using a mixed solution of water and an alcohol is especially preferable. Methanol, ethanol, propanol, butanol, etc., may be cited as the alcohol and ethanol is preferable. The weight ratio of water/the alcohol is preferably 1/100 to 100/1.
BACKGROUND: Cerebro-costo-mandibular syndrome (CCMS) is a rare congenital syndrome consisting of the main features of micrognathia and posterior rib gaps. Due to multiple abnormalities, patients almost have difficulty breathing with upper airway obstruction, decreased thoracic capacity, spina bifida, and scoliosis.
CASE PRESENTATION: We describe a case of a late preterm neonate boy presenting with low Apgar, respiratory distress, and complicated orofacial anomalies that had a poor outcome. His radiographic findings showed mandibular hypoplasia (micrognathia), chest deformity, multiple posterior rib gap defects, and abnormal costotransverse articulation. Based on physical examination and radiologic findings, the diagnosis of CCMS confirmed for the patient.
CONCLUSION: Physicians should always consider the diagnosis of CCMS in all infants with micrognathia and rib-gap defects. These infants need careful respiratory function monitoring. Early airway management improves growth and development. In addition, their physical and psychological development should be assessed regularly.
Clinical-electroencephalogram (EEG), as well as etiological and prognostic data on subtypes of nonconvulsive status epilepticus (NCSE) are yet to be established. Objective: Evaluate the clinical semiology and EEG findings and prognostic data of older adults with NCSE. Methodology: Characterize the clinical-EEG and prognostic data in the subtypes of NCSE in older adults consecutively admitted to the emergency room of the Pontifícia Universidade Católica de Campinas (PUC-Campinas) University Hospital. Results: When evaluating 105 older adults with altered consciousness, it was possible to diagnose NCSE in 50 (47.6%) older adults, with a mean age of 72.8 ± 8.8 years. NCSE-coma occurred in 6 cases, with NCSE-without coma in 44 cases. The etiology was structural in 41(82%) cases, metabolic in 5 cases, and unknown etiology in 4 cases. Twelve cases had a history of epileptic seizures. On the EEG, epileptiform discharges (EDs > 2.5 Hz) were present in 34(68%) cases and rhythmic delta activity /lateralized periodic patterns occurred in 35(70%) cases. There was clinical improvement after the initial pharmacological treatment in 36 cases and, within 30 days, 18 cases died. The better prognosis was associated with a good response to initial pharmacological treatment (n = 14) and with EDs > 2.5 Hz on EEG (Fisher's exact test; 26 vs 8; P = .012). Conclusion: Focal NCSE with impaired consciousness was the most frequent subtype. The most frequent finding on the EEG was the recording of focal/regional seizures. A high number of cases showed initial clinical improvement, but mortality was high. The favorable prognosis was associated with initial clinical improvement and the presence of EDs > 2.5 Hz. There was no relationship between EEG patterns and the etiology and subtypes of NCSE in older adults.
The patients whose blood pressure is not controlled under 120/80 with ARB alone are randomized into group A or B. In group B, blood pressure is controlled by Candesartan plus Imidapril.
Phenotypic transformation of pulmonary artery smooth muscle cells (PASMCs) contributes to vascular remodeling in hypoxic pulmonary hypertension (PH). Recent studies have suggested that circular RNAs (circRNAs) may play important roles in the vascular remodeling of hypoxia-induced PH. However, whether circRNAs cause pulmonary vascular remodeling by regulating the phenotypic transformation in PH has not been investigated. Microarray and RT-qPCR analysis identified that circLMBR1, a novel circRNA, decreased in mouse lung tissues of the hypoxia-SU5416 PH model, as well as in human PASMCs and mouse PASMCs exposed to hypoxia. Overexpression of circLMBR1 in the Semaxinib (SU5416) mouse model ameliorated hypoxia-induced PH and vascular remodeling in the lungs. Notably, circLMBR1 was mainly distributed in the nucleus and bound to the splicing factor PUF60. CircLMBR1 suppressed the phenotypic transformation of human PASMCs and vascular remodeling by inhibiting PUF60 expression. Furthermore, we identified U2AF65 as the downstream regulatory factor of PUF60. U2AF65 directly interacted with the pre-mRNA of the contractile phenotype marker smooth muscle protein 22-α (SM22α) and inhibited its splicing. Meanwhile, hypoxia exposure increased the formation of the PUF60-U2AF65 complex, thereby inhibiting SM22α production and inducing the transition of human PASMCs from a contractile phenotype to a synthetic phenotype. Overall, our results verified the important role of circLMBR1 in the pathological process of PH. We also proposed a new circLMBR1/PUF60-U2AF65/pre-SM22α pathway that could regulate the phenotypic transformation and proliferation of human PASMCs. This study may provide new perspectives for the diagnosis and treatment of PH.
Left Ventricular Dysfunction Following Myocardial Infarction: The basis for the beneficial effects of carvedilol in patients with left ventricular dysfunction following an acute myocardial infarction is not established. 

Hypertension: The mechanism by which β-blockade produces an antihypertensive effect has not been established.

β-adrenoreceptor blocking activity has been demonstrated in animal and human studies showing that carvedilol (1) reduces cardiac output in normal subjects; (2) reduces exercise and/or isoproterenol-induced tachycardia; and (3) reduces reflex orthostatic tachycardia. Significant β-adrenoreceptor blocking effect is usually seen within 1 hour of drug administration. 

α1-adrenoreceptor blocking activity has been demonstrated in human and animal studies, showing that carvedilol (1) attenuates the pressor effects of phenylephrine; (2) causes vasodilation; and (3) reduces peripheral vascular resistance. These effects contribute to the reduction of blood pressure and usually are seen within 30 minutes of drug administration.

Due to the α1-receptor blocking activity of carvedilol, blood pressure is lowered more in the standing than in the supine position, and symptoms of postural hypotension (1.8%), including rare instances of syncope, can occur. Following oral administration, when postural hypotension has occurred, it has been transient and is uncommon when carvedilol is administered with food at the recommended starting dose and titration increments are closely followed [see Dosage and Administration (2)]. 

In hypertensive patients with normal renal function, therapeutic doses of carvedilol decreased renal vascular resistance with no change in glomerular filtration rate or renal plasma flow. Changes in excretion of sodium, potassium, uric acid, and phosphorus in hypertensive patients with normal renal function were similar after carvedilol and placebo. 

Carvedilol has little effect on plasma catecholamines, plasma aldosterone, or electrolyte levels, but it does significantly reduce plasma renin activity when given for at least 4 weeks. It also increases levels of atrial natriuretic peptide.
The present invention relates to a two-component type composition for a cosmetic pack and patch, wherein the composition of a first agent is a liquid gel having flowability, and is applied to skin, thereby providing moisture and nutrition, and a second agent is applied to form a solid gel through an ionic bond so as to reduce the amount of volatilization or loss of moisture and nutrition when applied to skin and to ensure continuous provision of moisture and nutrition to skin. The composition may comprise: a first agent which has a viscous dosage form, i.e. a liquid gel, cream, lotion, or essence, and which comprises water-soluble anionic high-molecules that can form a solidified gel through an ionic bond; and a second agent which has a liquid form and contains bivalent to polyvalent cationic materials which can promote an ionic bond with the water-soluble anionic high-molecules of the first agent. In a different embodiment, a first agent has a viscous form, such as a liquid gel, cream, or lotion, and can use water-soluble cationic high-molecules that can form a solidified gel through an ionic bond, and a second agent has a liquid form and contains bivalent to polyvalent anionic materials that can promote an ionic bond with the water-soluble cationic high-molecules of the first agent. By applying the first agent, prepared as described, to skin, and then gelling the first agent by applying the second agent, similar effects as a solid-state pack, such as a hydrogel pack, modeling pack, and plaster pack, can be obtained. Various functional makeup components or medical skin cosmetic treatment components (for whitening, reducing wrinkles, blocking UV rays, regenerating cells, moisturizing, increasing skin elasticity, removing dead skin and sebum, treating atopy, acne, and wounds, alleviating inflammation and pain, and providing cool-feeling and warm-feeling effects), and 0.001~5 wt% of a preservation agent can be included in the composition of the first or the second agent, so that users can choose the cosmetic components that they want in order to provide cosmetic components to skin. The composition has other advantages in that the transformation of the liquid cosmetic product into a solid-state hydrogel pack can provide visual amusement while having a skin lifting effect, and removing the product after usage is easy as the product is of a peel-off type. In addition, compared to a solid-state hydrogel pack, which has recently been in the spotlight among consumers, the new dosage form of the present invention, having a two-component type cosmetic composition, can reduce the cost burden on consumers, which may be incurred due to a complex manufacturing process and high manufacturing and subsidiary material costs.
Personal care compositions comprise (a) from about 5 wt. % to about 50 wt. % of a detersive surfactant, (b) from about 0.05 wt. % to about 20 wt. % of wax particles having a melting point of at least about 100° C. and an average mean particle size as measured in said personal care composition of less than about 0.15 μm; and (c) at least about 20 wt. % of a cosmetically acceptable medium; wherein the personal care composition is substantially clear.
An assembling tool includes a controlling base with a top plate, and the controlling base has a controlling unit thereinside. There has a first fixing unit, a second fixing unit, a wheel unit, a motor-fixing unit, a driving unit and a measurement unit on the top plate, and the controlling unit is used for controlling these units on the top plate. The two sides of a roller are respectively holden by the first fixing unit and the second fixing unit. The front end of the roller further connects to the first wheel of wheel unit. A motor is disposed on the motor-fixing base of the motor-fixing unit and the motor is connected to the second wheel of the wheel unit. A belt winds around the first wheel and the second wheel. The driving unit moves the motor-fixing base so that the second wheel is moved to tie the belt. When the belt is at the tied state, the measurement unit is used to measure the tension of the belt.
A system for diagnosing a patient's joint disorder. A patient is fitted with a body suit, which can comprise one or more straps, sleeves, or the like. Sensors in the suit are placed around a problematic joint. The patient executes a number of selected ranges of motion, or tests and transmits signals indicative of pain level at different positions. A computer system receives the captured motion data and pain data and compares same to stored data sets. The stored data sets may comprise other motion data and/or pain data from the patient being examined, or captured data from other patients. The stored data sets can also be tagged with, or otherwise associated with, a diagnosis, model can be formed with respect to the patient's captured motion and pain information. A probable diagnosis of the joint disorder, effectiveness of the patient's treatment regimen, and disorder progression can be ascertained.
The present invention discloses a gene with a positive regulation and control function to a tumor cell cycle, a coding protein thereof and the application thereof. The present invention aims to provide a gene with a positive regulation and control function to a tumor cell cycle, a coding protein thereof and the application of the gene for preparing anti-tumor drugs. The cDNA of the gene is one of the following nucleotide sequences: a DNA sequence of SEQ ID No. 1 in a sequence table, a DNA sequence of SEQ ID No. 2 in a coding sequence table, and a nucleotide sequence hybridized with a DNA sequence limited by the SEQ ID No. 1 in the sequence table under a high-strict condition. The present invention provides reference to design and select a specific and effective molecule marker for the early diagnosis of tumors aiming at CREPT and an RNAi gene engineering drug for treating tumors so that the special gene diagnosis and the gene therapy for tumors are probable. The present invention has positive significance for the timely monitoring, the early detection, the early diagnosis and the early treatment of tumors and the reduction of the morbidity and the mortality of tumors.
The present invention relates to a yi'ejing tablet containing extractives of ant and moth for nourishing kidney and tonifying yang. 50 to 70% of nutrition substance for nourishing the kidney and strengthening yang and 30 to 50% of excipient are uniformly mixed and pressed to tablets. The excipient can be prepared by 50% of lactose, 48% of starch and 2% of stearic acid. The present invention is characterized in that nutrition substance for nourishing the kidney and strengthening yang is mixed and prepared from 30 to 100g of ant extract, 3 to 10g of male moth extract, 1 to 15g of dragonfly extract, 3 to 8g of penis cervi extract 1 to 3g of antler extract, 1 to 4g of sea horse extract, 2 to 20g of broomrape extract, 3 to 20g of epimedium extract, 1 to 15g of barbary wolfberry fruit extract and 1 to 5g of ginseng extract. The present invention has the functions of tonifying the liver and the kidney, strengthening the stomach and the spleen, promoting generation of vital essence and blood, strengthening yang, preventing prospermia, preventing fatigued spirit and lack of strength, etc. The present invention has no side effect to a human body.
Lidocaine/Bupivacaine mixture - 5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.